IPP Bureau
.jpg "Emcure Pharma files DRHP for proposed IPO, offer size in the range Rs 4,500-5000 crores")
Emcure Pharma files DRHP for proposed IPO, offer size in the range Rs 4,500-5000 crores
By IPP Bureau - August 20, 2021
In FY21, the company reported a net profit of Rs 419 crores compared to Rs 101 crores in FY 20 and consolidated total income at Rs 6092 crores, up 19% Y-o-Y
HealthCare at Home acquires SuVitas
By IPP Bureau - August 20, 2021
The acquisition expands the company’s service portfolio in the transition care segment
Kauvery hospitals rope in Ms Dhoni as brand ambassador
By IPP Bureau - August 20, 2021
Kauvery group of hospitals, a leading healthcare chain in Tamil Nadu, has roped in former Indian cricket captain Mahendra Singh Dhoni as its brand ambassador
Jehangir Hospital launches upgraded centre for Endoscopy
By IPP Bureau - August 20, 2021
The Endosonography allows the use of EUS guided Fine needle aspiration for accurate diagnosis of GI cancers without the need for conventional biopsies
US FDA approves Jardiance to treat adults living with heart failure with a reduced ejection fraction
By IPP Bureau - August 20, 2021
New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis. Heart failure accounts for more than one million hospitalisations a year in the US
Caspian Debt to fund healthcare companies, partners Samridh
By IPP Bureau - August 20, 2021
Caspian Debt has in principle committed up to Rs 35 crores to SAMRIDH’s commercial debt investment pool
Navia Life Care raises US $ 1 million in Series A funding
By IPP Bureau - August 20, 2021
The company plans to invest in technology, business development, product innovation, and development across India
US district court favours Pharmacyclics against Natco on Imbruvica
By IPP Bureau - August 20, 2021
In 2018 NATCO and Alvogen had filed an Abbreviated New Drug Application (ANDA) with PIV certification for the generic version of the product
Enzene Biosciences obtains DCGI approval for Romiplostim biosimilar
By IPP Bureau - August 20, 2021
It is the only biopharmaceutical company in India to offer all three dosage strengths of the drug (125mcg, 250mcg, and 500mcg)
Zydus ties up with CHEMI to launch Enoxaparin Sodium injection in the US
By IPP Bureau - August 20, 2021
Enoxaparin Sodium Injection, USP is used for prophylaxis of Deep Vein Thrombosis (DVT) in patients undergoing abdominal, hip or knee replacement surgery, and also for the treatment of acute DVT
AstraZeneca-Sputnik V combination demonstrates high immunogenicity profile: RDIF
By IPP Bureau - August 20, 2021
Preliminary data from the first 20 participants in Azerbaijan show antibodies to the SARS-CoV-2 virus spike protein (S-protein) elicited in 100% of cases
Zydus Cadila receives Emergency Use Authorisation for 3-dose ZyCoV-D vaccine
By IPP Bureau - August 20, 2021
This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC
Second-Gen mRNA COVID-19 vaccine candidate CV2CoV show positive signs in preclinical study
By IPP Bureau - August 19, 2021
The preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
Agilent Technologies Foundation partners with five hospitals for Covid-19 research
By IPP Bureau - August 19, 2021
Agilent Technologies Inc. announced the contribution of Agilent AriaMx Real-Time qPCR instruments to five research hospitals in India to support their COVID-19 initiatives and help them serve the community at large
Semglee approval to provide huge opportunities in the US insulin biosimilar market
By IPP Bureau - August 19, 2021
FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.
